The longstanding dominance of triptans in migraine treatment may be shifting as newer non-vasoconstrictive alternatives demonstrate superior real-world performance. This finding challenges the established treatment hierarchy and offers hope for patients who experience cardiovascular contraindications or inadequate response with traditional therapies.
Analysis of 1,570 migraine sufferers using the Migraine Buddy app revealed that gepant users achieved 36% higher odds of sustained 24-hour pain relief compared to triptan users, with an adjusted odds ratio of 1.36. The study population was predominantly female (91.2%) with a mean age of 43 years, reflecting typical migraine demographics. While both drug classes showed measurable efficacy, the gepants' advantage in prolonged relief represents a clinically meaningful difference that could influence prescribing decisions.
This real-world evidence fills a critical gap in migraine therapeutics, as head-to-head clinical trials between these drug classes remain scarce. The findings suggest gepants may offer particular value for patients seeking sustained relief beyond the initial treatment window. However, several limitations temper these results: the study relies on self-reported outcomes through a smartphone app, potentially introducing selection bias toward tech-savvy users, and cross-sectional design prevents causal inferences. Additionally, the analysis doesn't account for medication costs, accessibility, or individual contraindication profiles that heavily influence real-world prescribing patterns. While promising, this single observational study requires replication in controlled settings before fundamentally altering clinical practice guidelines for acute migraine management.